Harnessing the microbiome:a new frontier in lung cancer immunotherapyOA
Harnessing the microbiome:a new frontier in lung cancer immunotherapy
Kexin Feng;Jun Wang;Shuai Wang;Zewen Sun;Mantang Qiu;Zuli Zhou;Yun Li;Kezhong Chen
Department of Thoracic Surgery,Peking University People's Hospital,Beijing 100044,China||Thoracic Oncology Institute,Peking University People's Hospital,Beijing 100044,China||Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer,Chinese Academy of Medical Sciences,Peking University People's Hospital,Beijing 100044,ChinaDepartment of Thoracic Surgery,Peking University People's Hospital,Beijing 100044,China||Thoracic Oncology Institute,Peking University People's Hospital,Beijing 100044,China||Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer,Chinese Academy of Medical Sciences,Peking University People's Hospital,Beijing 100044,ChinaDepartment of Thoracic Surgery,Peking University People's Hospital,Beijing 100044,China||Thoracic Oncology Institute,Peking University People's Hospital,Beijing 100044,China||Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer,Chinese Academy of Medical Sciences,Peking University People's Hospital,Beijing 100044,ChinaDepartment of Thoracic Surgery,Peking University People's Hospital,Beijing 100044,China||Thoracic Oncology Institute,Peking University People's Hospital,Beijing 100044,China||Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer,Chinese Academy of Medical Sciences,Peking University People's Hospital,Beijing 100044,ChinaDepartment of Thoracic Surgery,Peking University People's Hospital,Beijing 100044,China||Thoracic Oncology Institute,Peking University People's Hospital,Beijing 100044,China||Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer,Chinese Academy of Medical Sciences,Peking University People's Hospital,Beijing 100044,ChinaDepartment of Thoracic Surgery,Peking University People's Hospital,Beijing 100044,China||Thoracic Oncology Institute,Peking University People's Hospital,Beijing 100044,China||Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer,Chinese Academy of Medical Sciences,Peking University People's Hospital,Beijing 100044,ChinaDepartment of Thoracic Surgery,Peking University People's Hospital,Beijing 100044,China||Thoracic Oncology Institute,Peking University People's Hospital,Beijing 100044,China||Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer,Chinese Academy of Medical Sciences,Peking University People's Hospital,Beijing 100044,ChinaDepartment of Thoracic Surgery,Peking University People's Hospital,Beijing 100044,China||Thoracic Oncology Institute,Peking University People's Hospital,Beijing 100044,China||Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer,Chinese Academy of Medical Sciences,Peking University People's Hospital,Beijing 100044,China
Lung cancerimmunotherapymicrobiomebiomarkersgut-lung axismicrobial metabolites
Lung cancerimmunotherapymicrobiomebiomarkersgut-lung axismicrobial metabolites
《癌症生物学与医学(英文版)》 2026 (8)
1057-1086,30
This work was supported by the Beijing Natural Science Foundation(Grant Nos.Z240013,L234002,and L222021),the Beijing Research Ward Excellence Program(Grant Nos.BRWEP2024W034080200 and BRWEP2024W034080204),the Chinese Academy of Medical Sciences(Grant No.2021RU002),the National Natural Science Foundation of China(Grant Nos.92259303,82388102,82450111,82373416,and 82573950),the CAMS Medical and Health Science and Technology Innovation Project(Grant No.2021-I2M-5-002),and the Peking University People's Hospital Research and Development Funds(Grant No.RZG2024-02).
评论